Iloperidone - A second-generation antipsychotic for the treatment of acute schizophrenia

Journal of Pharmacy Technology

Volumn 26, Issue 4, 2010, Pages 193-202

  Hale, Katherine S ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUOXETINE; HALOPERIDOL; ILOPERIDONE; ITRACONAZOLE; KETOCONAZOLE; METHADONE; MOXIFLOXACIN; O DEMETHYLASE; PAROXETINE; QUINIDINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; CLINICAL EVALUATION; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LABELING; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYDROXYLATION; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LACTATION; LEUKOPENIA; MEDLINE; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PLASMA PROTEIN BINDING; POSITIVE AND NEGATIVE SYNDROME SCALE; PREGNANCY; PRIAPISM; PROLACTIN BLOOD LEVEL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDE; SYNCOPE; TACHYCARDIA; TARDIVE DYSKINESIA; THERMOREGULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; WEIGHT; WEIGHT GAIN; XEROSTOMIA;

EID: 77957359401     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512251002600404     Document Type: Review

References (34)

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd edition, 2004. www.psychiatryonline.com/ pracGuide/pracGuideChapToc-6.aspx (accessed 2010 Jan 11). DOI 10.1176/appi.books.9780890423363.45859
2. Crimson ML, Argo TR, Buckley PF. Schizophrenia. In: Dipiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy - a pathophysiologic approach. 7th ed. New York NY: McGraw-Hill 2008: 1099-122.
3. Buchanan RW, Carpenter WT, Lauriello J, et al. Schizophrenia and other psychotic disorders. In: Sadock BJ, Sadock VA, eds. Comprehensive textbook of psychiatry. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:1329-1558.
4. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry 1999;60(supp 1):4-6.
5. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004; 30:279-93.
6. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:56-72. DOI 10.1016/S0006 = 3223(99)00067-0
7. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
8. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000;287:2020-2. DOI 10.1126/science.287.5460.2020
9. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy, and tolerability. Drugs 2008;68:2269-92. DOI 10.2165/0003495-200868160-00002
10. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104. DOI 10.1038/sj.mp.4001556
11. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389-409. DOI 10.2165/00023210-200620050-00004
12. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. DOI 10.1056/NEJMoa051688
13. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96. (Pubitemid 29517559)
14. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28. DOI 10.1001/archpsyc.62.1.19
15. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure and the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6. DOI 10.1001/archpsyc.59.11.1021
16. Package insert. Fanapt (iloperidone). Rockville, MD: Vanda Pharmaceuticals, Inc., 2009.
17. Szewczak MR, Corbett R, Rush DK, et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 1995;274:1404-13.
18. 2C, 5-HT6, and 5-HT1A receptors. Life Sci 2003;73:1151-9. DOI 10.1016/S0024-3205(03)00419-3
19. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-14. DOI 10.1016/S0893-133X(01)00285-8
20. Subramanian K, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:553-63. DOI 10.1016/S0278-5846(01)00307-4
21. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol 1995;35:713-20. Erratum. J Clin Pharmacol 1996;36:92.
22. Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70:801-9. DOI 10.4088/JCP.08m04391
23. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28:S4-11. DOI 10.1097/JCP.0b013e3181692787
24. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28:S20-8. DOI 10.1097/JCP.0b013e318169d4ce (Pubitemid 351397673)
25. Kane JM, Lauriello J, Laska E, Di Marino M, Wolgang CD. Long-term efficacy and safety of iloperidone. J Clin Psychopharmacol 2008;28:S29-35. DOI 10.1097/JCP0b013e318169cca7
26. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261-76. (Pubitemid 18039085)
27. Thompson PA, Buckley PF, Meltzer HY. The brief psychiatric rating scale: effect of scaling system on clinical response assessment. J Clin Psychopharmacol 1994;14:344-6. DOI 10.1097/00004717-199410000-00010
28. Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophen Res 2005;76:247-65. DOI 10.1016/j.schres.2005.02.013 (Pubitemid 40804771)
29. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperodone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28:S12-9. DOI 10.1097/JCP0b013e3181694f5a
30. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43. DOI 10.1001/jama.294.15.1934 (Pubitemid 41464695)
31. Wang PS, Schneeweiss S, Avom J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005;353:2335-41. DOI 10.1056/NEJMoa052827
32. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol 2009;8:151-7. DOI 10.1016/S1474-4422(08) 70295-3
33. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82. DOI 10.1176/appi.ajp.158.11.1774
34. Barrett E, Blonde L, Clement S, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601. DOI 10.2337/diacare.27.8.2089